A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

Expanded access is no longer available for this treatment.
(Company decision to cancel due to public funding)
Sponsor:
Collaborator:
Ortho Biotech Canada
Information provided by (Responsible Party):
Janssen-Ortho Inc., Canada
ClinicalTrials.gov Identifier:
NCT00799539
First received: November 26, 2008
Last updated: November 30, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is no longer available for this treatment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given